The first cohort of participants has been dosed in a Phase I trial MTX-474, a human IgG1 antibody designed to neutralise EphrinB2 signalling to treat fibrosis.

The study, taking place in Australia, is designed to assess the safety, tolerability, pharmacokinetics, and target engagement of MTX-474 in healthy participants.

Ephrin ligands and Eph receptors mediate biological processes involved in tissue fibrosis including cell migration, myofibroblast activation, and tissue remodelling. A growing body of evidence has implicated EphrinB2 in the fibrosis of the skin, lungs, and heart.

Mediar Therapeutics has also reported continued progress in its US Phase I study of WISP1 targeting antibody, MTX-463, with approximately three quarters of the cohorts dosed, and completion of the trial expected by the end of 2024.

Additionally, MTX-463 was granted orphan drug and fast track designations by the FDA, underscoring the potential of WISP1 to address significant unmet needs in treating rare fibrotic diseases, including idiopathic pulmonary fibrosis (IPF).

WISP1 is a secreted matricellular protein shown to have a relevant role in fibrosis progression, measurable in human blood, and correlates with disease severity. Initial data indicates that MTX-463 neutralises WISP1-mediated fibrotic signalling that spans several fibrotic indications and significantly reduced fibrosis in vitro and in preclinical mouse models.

“I am excited about the emerging clinical portfolio at Mediar and its unique approach to directly target the myofibroblast, the key pathogenic cell in fibrosis,” said Toby Maher, Professor of Medicine and Director of Interstitial Lung Diseases at University of Southern California, and member of Mediar’s Clinical Advisory Board. “Both the EphrinB2 and WISP1 antibody programmes offer potential novel approaches to halt and maybe even reverse fibrosis. I look forward to completion of the Phase I studies and future planned Phase II trials in systemic sclerosis and IPF, respectively.”

Diana Spencer, Senior Digital Content Editor, DDW